HCWB
HCW Biologics Inc.1.7800
-0.0860-4.61%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.81MP/E (TTM)
-Basic EPS (TTM)
-13.81Dividend Yield
0%Recent Filings
8-K
HCW regains Nasdaq compliance
HCW Biologics tackled its Nasdaq equity deficiency with a $3.8M warrant inducement on November 19, 2025, $363,858 from its equity line, and a December 30 settlement slashing $7.4M legal fees to $2.0M cash plus contingent note—yielding ~$5.4M equity boost. These moves pushed stockholders' equity over $2.5M by year-end, meeting the Equity Rule before the December 31 deadline. Nasdaq confirmation pending.
8-K
Warrant inducement yields $4M
HCW Biologics induced a single institutional investor to exercise 1,510,205 existing warrants at a reduced $2.66 per share, netting ~$4.0M gross proceeds before fees. In exchange, it issued new warrants for 3,020,410 shares at $2.41, exercisable immediately through mid-2031. Cash bolsters runway, but doubles potential dilution. Deal closed November 20, 2025.
8-K
Restructured HCW11-006 license deal
HCW Biologics inked an Amended and Restated License with Beijing Trimmune Biotech on November 17, 2025, restructuring the HCW11-006 in vivo license deal. HCW pays $3.5M cash plus Trimmune equity upfront, gains an option for HCW9302 in China/Asia, while Trimmune funds all R&D and commercialization costs outside the Opt-in Territory. It holds a free recapture option post-Phase 1 in the Americas. Closing must happen by January 16, 2026—or rights revert.
8-K
First patient dosed in HCW9302 trial
HCW Biologics dosed its first patient on November 17, 2025, in a multi-center Phase 1 trial of lead candidate HCW9302 for alopecia areata at The Ohio State University Wexner Medical Center. The subcutaneously injectable IL-2 fusion aims to expand Treg cells, curbing inflammation without broad immunosuppression. First-in-human milestone. Trial targets safety in up to 30 patients, eyeing Phase 2 expansion amid enrollment risks.
10-Q
Q3 FY2025 results
HCW Biologics posted a Q3 net loss of $4.6M, up 17% y/y, with diluted EPS improving to $(2.02) from $(4.13) on higher shares (2.26M vs 0.95M). Revenues crashed 96% y/y to $16K from Wugen supply amid license suspension, while R&D rose 18% to $1.4M on preclinical work for TRBC molecules; legal recoveries swung YTD to a $1.6M gain from insurance. Cash fell to $1.1M after $10M op cash burn, offset by $6.5M equity raises and $7.7M debt conversions to stock/warrants/rights on Wugen shares (now $1.3M investment). Short-term debt sits at $6.8M, including $6.2M Cogent loan (5.75%, 2027 maturity) under mechanics lien pressure. Nasdaq granted compliance extension to Dec 31. Construction liens loom large.
CUE
Cue Biopharma, Inc.
0.41-0.05
HOTH
Hoth Therapeutics, Inc.
1.05-0.04
HOWL
Werewolf Therapeutics, Inc.
1.08+0.05
IMTX
Immatics N.V.
10.09+0.11
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
INAB
IN8bio, Inc.
1.50-0.10
INMB
INmune Bio Inc.
1.89-0.02
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
QTTB
Q32 Bio Inc.
2.88-0.17
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03